iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004 iRegene Hits Dual Global Firsts: U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results